Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology

被引：1

作者：

Zhu, Yu-Jin ^{[1
]}

Zhang, Yan ^{[2
]}

Rao, Yao ^{[3
]}

Jiang, Yong ^{[4
]}

Liu, Yong-Gang ^{[5
]}

Li, Jian-Zhou ^{[6
]}

Yuan, Jia-Qi ^{[6
]}

Zhao, Ying ^{[2
]}

Zheng, Wen-Wen ^{[2
]}

Ma, Lin ^{[2
]}

Wang, Chun-Yan ^{[3
]}

Li, Jia ^{[3
]}

机构：

[1] Northwest Univ, Xian Hosp 3, Affiliated Hosp, Dept Infect Dis, Xian 710018, Shaanxi, Peoples R China

[2] Tianjin Med Univ, Dept Epidemiol, Tianjin 300070, Peoples R China

[3] Second Peoples Hosp, Clin Sch, Dept Gastroenterol, 7 Sudi South Rd, Tianjin 300110, Peoples R China

[4] Tianjin Med Univ, Hosp 2, Dept Gastroenterol, Tianjin 300211, Peoples R China

[5] Second Peoples Hosp, Clin Sch, Dept Pathol, Tianjin, Chin, Myanmar

[6] Xining Second Peoples Hosp, Dept Gastroenterol, Xining 810003, Qinghai, Peoples R China

来源：

WORLD JOURNAL OF HEPATOLOGY | 2024年 / 16卷 / 12期

关键词：

Nonalcoholic fatty liver disease; Liver pathology; Autoantibody; Autoimmunity; Clinical indicator; KILLER T-CELLS; ANTINUCLEAR ANTIBODIES; CLINICAL-SIGNIFICANCE; HEPATITIS; PREVALENCE; AUTOANTIBODIES; INFLAMMATION; FIBROSIS; NAFLD;

D O I：

10.4254/wjh.v16.i12.1407

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND Autoimmune phenomena can be used in some patients with nonalcoholic fatty liver disease (NAFLD) in the clinic, but these patients are not autoimmune hepatitis patients. AIM To determine whether autoimmunity is present in patients with NAFLD, this study was performed. METHODS A total of 104 patients with NAFLD diagnosed by liver biopsy at Tianjin Second People's Hospital between 2019 and 2023 were enrolled. The patients were divided into three groups according to their biopsy results: The NAFL (n = 36), nonalcoholic steatohepatitis (n = 51), and liver cirrhosis groups (n = 17). RESULTS The differences in IgA, an immune marker, among the three groups of patients were statistically significant (P = 0.025). In all NAFLD patients, antinuclear antibody and anti-smooth muscle antibody were the most common autoantibodies. The antinuclear antibody detection rate was the highest at 48.1%. The cirrhosis group had the highest autoantibody positivity rate (64.7%). Portal enlargement is also common in NAFLD patients. The rates of positivity for portal lymphoplasmacytic infiltration, small bile duct hyperplasia and interfacial hepatitis were highest in the cirrhosis group; the differences between the cirrhosis group and the other two groups were significant (P < 0.05). Hepatocellular rosettes were identified only in the cirrhosis group (11.8%). CONCLUSION Autoimmune phenomena occur in NAFLD patients, especially in patients with NAFLD-related cirrhosis, in whom this phenomenon may be more pronounced.

引用

页码：1407 / 1416

页数：11

共 31 条

[1] Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update, Zhonghua Gan Zang Bing Za Zhi, 26, pp. 195-203, (2018)
[2] Shi YW, Xiao QQ, Fan JG., Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease, Zhonghua Gan Zang Bing Za Zhi, 28, pp. 915-917, (2020)
[3] Luo L, Ma Q, Lin L, Wang H, Ye J, Zhong B., Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis, Dis Markers, 2022, (2022)
[4] Jim M., The prevalence and significance of autoantibodies in patients with nonalcoholic steatohepatitis, Zhongguo Shiyong Neike Zazhi, 27, pp. 360-362, (2007)
[5] Deng CJ, Lo TH, Chan KY, Li X, Wu MY, Xiang Z, Wong CM., Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update, Int J Mol Sci, 23, (2022)
[6] Dalekos GN, Gatselis NK., Autoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis, Eur J Intern Med, 108, pp. 9-17, (2023)
[7] Tian AP, Yang YF., Diagnosis of nonalcoholic fatty liver disease: The importance of pathology, Linchuang Ganbingxue Zazhi, 39, pp. 491-497, (2023)
[8] Guidelines on the diagnosis and management of autoimmune hepatitis (2021)], Zhonghua Gan Zang Bing Za Zhi, 30, pp. 482-492, (2022)
[9] Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Muhlen CA, Andrade LE., Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015, Front Immunol, 6, (2015)
[10] Pierantonelli I, Svegliati-Baroni G., Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH, Transplantation, 103, pp. e1-e13, (2019)

← 1 2 3 4 →